ES2659264T3 - Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS - Google Patents

Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS Download PDF

Info

Publication number
ES2659264T3
ES2659264T3 ES12824342.5T ES12824342T ES2659264T3 ES 2659264 T3 ES2659264 T3 ES 2659264T3 ES 12824342 T ES12824342 T ES 12824342T ES 2659264 T3 ES2659264 T3 ES 2659264T3
Authority
ES
Spain
Prior art keywords
patients
colorectal cancer
mutation
patient
tas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12824342.5T
Other languages
English (en)
Spanish (es)
Inventor
Masanobu Ito
Hiroyuki Okabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2659264T3 publication Critical patent/ES2659264T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
ES12824342.5T 2011-08-16 2012-08-15 Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS Active ES2659264T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011177838 2011-08-16
JP2011177838 2011-08-16
PCT/JP2012/070745 WO2013024865A1 (ja) 2011-08-16 2012-08-15 Kras遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法

Publications (1)

Publication Number Publication Date
ES2659264T3 true ES2659264T3 (es) 2018-03-14

Family

ID=47715182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12824342.5T Active ES2659264T3 (es) 2011-08-16 2012-08-15 Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS

Country Status (21)

Country Link
US (1) US9371380B2 (enExample)
EP (1) EP2746404B1 (enExample)
JP (1) JP5832541B2 (enExample)
KR (1) KR101693090B1 (enExample)
CN (1) CN103764847B (enExample)
AU (1) AU2012295841B2 (enExample)
CY (1) CY1119869T1 (enExample)
DK (1) DK2746404T3 (enExample)
ES (1) ES2659264T3 (enExample)
HR (1) HRP20180130T1 (enExample)
HU (1) HUE035347T2 (enExample)
LT (1) LT2746404T (enExample)
NO (1) NO2746404T3 (enExample)
PL (1) PL2746404T3 (enExample)
PT (1) PT2746404T (enExample)
RS (1) RS56911B1 (enExample)
RU (1) RU2585528C2 (enExample)
SI (1) SI2746404T1 (enExample)
SM (1) SMT201800108T1 (enExample)
TW (1) TWI550089B (enExample)
WO (1) WO2013024865A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
UA123403C2 (uk) * 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
AU2017397458B2 (en) * 2017-02-01 2025-07-10 Modernatx, Inc. RNA cancer vaccines
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1849470T5 (pl) 2005-01-26 2024-06-10 Taiho Pharmaceutical Co., Ltd. Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej
US7799783B2 (en) 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor

Also Published As

Publication number Publication date
JPWO2013024865A1 (ja) 2015-03-05
JP5832541B2 (ja) 2015-12-16
NO2746404T3 (enExample) 2018-05-05
TW201319257A (zh) 2013-05-16
WO2013024865A1 (ja) 2013-02-21
RU2585528C2 (ru) 2016-05-27
TWI550089B (zh) 2016-09-21
EP2746404B1 (en) 2017-12-06
EP2746404A1 (en) 2014-06-25
SMT201800108T1 (it) 2018-05-02
RU2014109999A (ru) 2015-10-10
SI2746404T1 (en) 2018-04-30
DK2746404T3 (en) 2018-01-15
CY1119869T1 (el) 2018-06-27
HK1197086A1 (zh) 2015-01-02
HRP20180130T1 (hr) 2018-04-06
CN103764847B (zh) 2016-05-11
HUE035347T2 (en) 2018-05-02
PT2746404T (pt) 2018-01-10
PL2746404T3 (pl) 2018-04-30
CN103764847A (zh) 2014-04-30
KR20140057328A (ko) 2014-05-12
AU2012295841B2 (en) 2015-12-10
RS56911B1 (sr) 2018-05-31
EP2746404A4 (en) 2015-04-08
US9371380B2 (en) 2016-06-21
AU2012295841A1 (en) 2014-04-03
LT2746404T (lt) 2018-04-25
US20140213602A1 (en) 2014-07-31
KR101693090B1 (ko) 2017-01-04

Similar Documents

Publication Publication Date Title
Silvera et al. Translational control in cancer
JP6193268B2 (ja) Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
JP2023512039A (ja) 化合物及びその使用
ES2659264T3 (es) Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS
ES2953005T3 (es) Tratamiento para el cáncer
ES2968789T3 (es) Procedimiento combinado para el tratamiento del cáncer
JP6823587B2 (ja) Mdm2阻害剤とbtk阻害剤との併用治療法
US20210214390A1 (en) Rapaglutins, novel inhibitors of glut and use thereof
BR112020008537A2 (pt) inibidores duplos de vias da tim-3 e da pd-1
JP2023512181A (ja) 癌を治療するためのegfr阻害剤とror1阻害剤の組み合わせ
US20120156310A1 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
WO2025075211A1 (en) Alisertib and paclitaxel for treating small cell lung cancer
ES2362115T3 (es) Composición farmacéutica para su uso en el tratamiento de individuos que presentan proteína kit mutante.
Duffy et al. Kinase Inhibition for Immuno-oncology
HK1197086B (en) Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
Govind Babu et al. Adjuvant and Neoadjuvant
JPWO2010074240A1 (ja) 化学療法の治療効果予測方法
Fiebig et al. 282 POSTER 5-Methyl-indirubin: a CDK-inhibitor with activity in human tumor models in vivo
Camidge et al. 281 POSTER A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results
Ducommun et al. 280 POSTER Targeting CDC25 phosphatases in cancer therapy
Bhattacharya et al. 251 ORAL The phosphatidylinositide 3-kinase (P13-kinase) inhibitor Pl103 sensitises some ovarian carcinoma (OC) cell lines to paclitaxel or carboplatin
WO2010074241A1 (ja) 併用化学療法の治療効果予測方法